Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $9.33, but opened at $9.66. Mesoblast shares last traded at $9.86, with a volume of 38,846 shares traded.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on MESO. Jefferies Financial Group raised Mesoblast from a "hold" rating to a "buy" rating in a research report on Thursday, August 29th. StockNews.com downgraded Mesoblast from a "hold" rating to a "sell" rating in a report on Wednesday, September 4th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Mesoblast in a report on Thursday, August 29th. Piper Sandler upgraded Mesoblast from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $4.00 to $11.00 in a research report on Tuesday, July 23rd. Finally, Maxim Group raised shares of Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 price target for the company in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $11.50.
Read Our Latest Research Report on Mesoblast
Mesoblast Trading Up 8.0 %
The firm's 50-day simple moving average is $6.97 and its 200-day simple moving average is $6.87. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.
Hedge Funds Weigh In On Mesoblast
A number of institutional investors and hedge funds have recently bought and sold shares of MESO. Chase Investment Counsel Corp acquired a new position in Mesoblast in the first quarter valued at about $298,000. GAMMA Investing LLC raised its position in shares of Mesoblast by 50.1% in the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company's stock valued at $34,000 after purchasing an additional 1,663 shares during the period. Perkins Coie Trust Co bought a new position in shares of Mesoblast in the second quarter valued at about $68,000. Chapin Davis Inc. raised its position in shares of Mesoblast by 50.0% in the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company's stock valued at $102,000 after purchasing an additional 5,000 shares during the period. Finally, Pine Valley Investments Ltd Liability Co acquired a new position in shares of Mesoblast in the second quarter valued at about $80,000. Institutional investors and hedge funds own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
